$169/mo
Tirzepatide
Weekly and dual-action. Care, coaching and shipping included.
Get startedHome / Is compounded tirzepatide legal?
Clear rules. Calm answers.
Is compounded tirzepatide legal, safe and still available in 2026?
Yes, compounded tirzepatide is legal when it’s prescribed for you: a state-licensed 503A pharmacy may make it for one patient when the prescriber documents a significant difference for them. Routine copies of Zepbound ended with the shortage (December 19, 2024), upheld on appeal on August 27, 2026.
- Legal: for an individual prescription (503A)
- Not: FDA-approved, or a generic
- Courts: upheld the FDA in August 2026
Published by NexLifeLegitScript-certifiedUpdated October 9, 2026 · First published October 3, 2026Medically reviewed by the NexLife clinical team, led by Adam Kennah, MD (NPI 1144260043)
The rules, in short
- Legal?
- Yes, for an individual prescription from a state-licensed 503A pharmacy
- FDA-approved?
- No, and it isn’t a generic
- 503B facilities
- Can’t make it from bulk tirzepatide
- The courts
- The Fifth Circuit upheld the FDA on August 27, 2026
- At NexLife
- Licensed physicians, named state-licensed pharmacies
Questions about the rules or your medication? Call or text (949) 818-8000, 24/7.
Start with tirzepatide, $169/mo
4.8 out of 5 on Trustpilot · LegitScript certified
The rules
The rules in 2026, in plain words
Compounded for you, by prescription. A state-licensed 503A pharmacy prepares it for an individual patient’s prescription.
Not a routine copy. A pharmacy can’t regularly copy an approved drug unless the prescriber documents a change that makes a significant difference for that patient.
A narrow allowance. The FDA says it won’t act against a pharmacy that fills four or fewer copies in a calendar month. That’s an enforcement policy, not a change in the law.
An added vitamin isn’t a loophole. In the FDA’s example, a GLP-1 with B12 can still count as essentially a copy when both amounts are within 10% of approved strengths.
Honest claims only. Companies can’t call compounded products generic, the same as Zepbound or Wegovy, or proven. In March 2026, the FDA warned 30 telehealth companies over claims like these.
Two pathways
503A pharmacies vs. 503B outsourcing facilities
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| What it is | A state-licensed pharmacy compounding for individual patients | A facility registered with the FDA as an outsourcing facility |
| Prescriptions | Compounds for an individual patient’s prescription | Can compound with or without one |
| Main oversight | State boards of pharmacy; the FDA can also inspect | The FDA, on a risk-based schedule |
| Federal manufacturing rules | Not subject to them | Subject to them |
| Tirzepatide in 2026 | For an individual prescription, when the prescriber documents a significant difference for that patient | Can’t compound it from bulk tirzepatide: it isn’t on the 503B bulks list or the shortage list |
| FDA-approved? | No | No |
Neither pathway makes a compounded drug FDA-approved. NexLife’s prescriptions are filled by state-licensed 503A pharmacies.
Clear rules. Calm answers.
The rules around compounded GLP-1s changed. Here is what they mean for you, without the noise.
- Rules changed. Both shortages were declared resolved, and the FDA restated what compounders may do.
- Headlines got loud. Some sounded like everything was ending. It isn’t that simple.
- Answers got vague. Too many pages skip the sources. Every rule here links to the FDA.
Prescribed for you, the way the rules intend.
- A physician decides. A licensed physician reviews your history before anything is prescribed.
- One flat price. $169 tirzepatide, $139 semaglutide, at every dose.
- Named pharmacies. State-licensed pharmacies, named on NexLife’s plan pages.
Real people, real answers. Call or text (949) 818-8000 with any question about your care.
Check my eligibility, $169/mo
Timeline
What changed, and when
From the FDA’s own updates and the court’s ruling.
After re-evaluating, the FDA confirms the tirzepatide shortage is resolved.
The FDA determines the semaglutide shortage is resolved.
The grace period ends for pharmacies making copies of tirzepatide: March 5 for 503A pharmacies, March 19 for 503B facilities.
The FDA announces steps against mass-marketed compounded GLP-1s and misleading ads.
The FDA warns 30 telehealth companies about false or misleading claims for compounded GLP-1s.
The FDA restates the conditions compounders must meet. Neither drug is in shortage.
The FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. Comments closed June 30.
The Fifth Circuit upholds the FDA’s decisions that the tirzepatide and semaglutide shortages are over.
At our latest check, we found no final FDA decision on the 503B proposal.
Two medications.
One flat price each.
Both are prepared by state-licensed 503A partner pharmacies and shipped free. Your provider helps you decide which one fits.
$139/mo
Semaglutide
Weekly GLP-1. Care, coaching and shipping included.
Get startedWhat’s inside every plan
- Tirzepatide: compounded, acts on two hormone pathways (GIP and GLP-1), taken once a week
- Semaglutide: compounded, acts on the GLP-1 pathway, taken once a week
- Prepared by state-licensed 503A partner pharmacies
- A licensed provider who reviews your history and follows your dose
- A personalized nutrition plan and a 1:1 coaching call
- Free expedited shipping; orders usually ship within 1 to 2 business days
- 24/7 support from real people, plus physician access during clinical hours
- HSA and FSA cards accepted, and Klarna or Afterpay at checkout
- Prefer no injections? Ask about the sublingual tablet, at its own flat price
Prescription required. Compounded medications are not FDA-approved. On 12-month plans: $139 a month for tirzepatide, $119 for semaglutide, still the same at every dose. Prices checked October 7–8, 2026.
Your dose goes up.
Your price doesn’t.
No membership, no dose surcharges, no surprises. One flat, all-inclusive monthly price at every dose.
| Month one | Month two | Month three | Every month after | |
|---|---|---|---|---|
| Tirzepatide | $169 | $169 | $169 | $169 |
| Semaglutide | $139 | $139 | $139 | $139 |
Paying less somewhere else? Send us a receipt from another licensed U.S. telehealth provider and we’ll match your regular monthly price. See the terms
Month-to-month plan, all-inclusive. Longer plans cost less and stay flat. Tirzepatide is $159, $149 and $139 a month on 3-, 6- and 12-month plans. Semaglutide is $132, $125 and $119.
What would you pay with NexLife?
Tap where you are now. We’ll show your NexLife price next to it, or tell you we’ll match it.
Pick one above to see your price.
Not today?
Prices from each provider, checked October 7–8, 2026. Brand-name and compounded medications are different products; compounded medications are not FDA-approved. †Price Match Guarantee terms apply.
The NexLife Price Match Guarantee
Keep your price.
Upgrade your care.
Already on compounded tirzepatide or semaglutide? Bring your price to NexLife. If you pay less with another licensed U.S. telehealth provider, we match your regular monthly price for as long as your plan stays active.† You keep your price, and you gain a provider who follows your dose, a personal nutrition plan, a 1:1 coaching call and real people who answer 24/7.
- 1Send a receipt from the last 60 days
- 2A NexLife provider reviews your prescription
- 3Pay your matched price, at every dose
Locked while your plan is activeSame price at every doseNo membership fee
†NexLife Price Match Guarantee: for new members switching from a licensed U.S. telehealth provider with an active prescription for compounded tirzepatide or semaglutide. Send a receipt from the last 60 days and we match your regular all-in monthly price on the month-to-month plan, for the same medication (medication plus required fees; not first-month offers, coupons or prepaid multi-month rates), for as long as your plan stays active. A NexLife provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.
Safeguards
What a licensed program looks like
The FDA warns about fraudulent compounded products with false labels. These are NexLife’s safeguards.
A licensed physician decides
NexLife prescriptions come only from licensed physicians with Nexlife Medical Group, after a review of your history.
Named, licensed pharmacies
Prescriptions are filled by Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA), each state-licensed, depending on your location, your provider’s direction and pharmacy availability.
Certified partners
NexLife is LegitScript-certified and works only with compounding pharmacies that are LegitScript-certified and accredited by the National Association of Boards of Pharmacy.
A real reason to compound
Compounded tirzepatide is available only if your prescriber determines that it provides a significant difference for you compared to an FDA-approved product.
Questions about your medication? Ask us.
Call or text (949) 818-8000, 24/7. We follow up with the pharmacy for you.
Is compounded tirzepatide legal? Your questions
Is compounded tirzepatide legal in 2026?
Yes, when a state-licensed 503A pharmacy prepares it for an individual prescription and the prescriber documents a significant difference for that patient. It isn’t FDA-approved.
Did the courts rule on compounded tirzepatide?
On August 27, 2026, the Fifth Circuit upheld the FDA’s decisions that the tirzepatide and semaglutide shortages are over. That limits copying, not individual prescriptions that meet the rules.
Is compounded tirzepatide being banned?
No ban has been announced. The FDA has proposed keeping tirzepatide off the 503B bulks list, which affects outsourcing facilities, not 503A prescriptions; we found no final decision as of October 8, 2026.
Is compounded tirzepatide a generic Zepbound?
No. There’s no FDA-approved generic tirzepatide, and compounded tirzepatide isn’t the same as Zepbound.
Is compounded tirzepatide safe?
It isn’t FDA-approved, so the FDA hasn’t reviewed it for safety, effectiveness or quality. A licensed prescriber, a state-licensed pharmacy and a label you can read lower the risks.
What’s the difference between 503A and 503B?
503A pharmacies compound for individual prescriptions under state boards; 503B outsourcing facilities register with the FDA. In 2026, 503B facilities can’t make tirzepatide from bulk ingredients.
Important safety information
Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Read the full safety information
In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath.
Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and depression or thoughts of suicide. Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other GLP-1 medicines.
Tirzepatide can make birth control pills less effective: use another method for 4 weeks after you start and after each dose increase. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider if you’re pregnant, planning to be, or breastfeeding.
This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at 1-800-FDA-1088 or fda.gov/medwatch.
Who checked this page
Adam Kennah, MDMedical Director, NexLife · Board-certified in emergency medicine · NPI 1144260043
Leads the NexLife clinical team, which medically reviewed this page on October 8, 2026.
NexLife editorial teamResearch and pricing
the FDA’s compounding rules and 2026 statements, the 503B bulks-list proposal and its comment period, the Fifth Circuit’s August 27, 2026 ruling, and NexLife’s physician and pharmacy disclosures
- Every fact, sourced. Each price and rule links to the page it comes from.
- How we make money. NexLife is a telehealth provider. We earn revenue when people join NexLife.
- Corrections, fast. See something wrong or out of date? Email care@nexlife.us and we’ll fix it.
Prescribed for you, the way the rules intend.
Start online in about 3 minutes. A licensed physician decides if tirzepatide is right for you.
- 1Tell us about you
A short online health assessment, about 3 minutes.
- 2A licensed provider reviews it
You’re prescribed only if treatment is right for you.
- 3We ship it, then stay with you
Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, 24/7 support.
Sources
- U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
- U.S. Food and Drug Administration. Compounding and the FDA: questions and answers.
- U.S. Food and Drug Administration. Guidance for entities considering whether to register as outsourcing facilities under section 503B.
- U.S. Food and Drug Administration. FDA intends to take action against non-FDA-approved GLP-1 drugs (February 6, 2026).
- U.S. Food and Drug Administration. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s (March 3, 2026).
- U.S. Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026).
- Federal Register. List of bulk drug substances for which there is a clinical need under section 503B (May 1, 2026).
- U.S. Court of Appeals for the Fifth Circuit. Outsourcing Facilities Association v. FDA, No. 25-10600 (Aug. 27, 2026).
- U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss.
- NexLife. Compounded tirzepatide plans.
- Eli Lilly and Company. Zepbound (tirzepatide) prescribing information.
- Novo Nordisk. Wegovy (semaglutide) prescribing information.
- LegitScript. Certification lookup for nexlife.us.
- NexLife. Compounded semaglutide plans.